# Supplementary Appendix
# FINE-TURK Major Revision

This appendix contains the complete missingness comparisons, subgroup estimates, sensitivity analyses, and supporting figures. All values are aggregate and contain no direct patient identifiers.

## Supplementary Table S1. Baseline characteristics according to complete versus incomplete follow-up

| Outcome | Variable | Complete n | Complete | Incomplete n | Incomplete | SMD | P |
|---|---|---|---|---|---|---|---|
| eGFR | Age, years | 571 | 60.19 ± 11.33 | 519 | 61.07 ± 11.65 | -0.076 | 0.115 |
| eGFR | Male sex | 571 | 328 (57.4%) | 520 | 272 (52.3%) | 0.103 | 0.089 |
| eGFR | BMI, kg/m² | 461 | 30.38 ± 5.84 | 395 | 30.46 ± 5.97 | -0.013 | 0.836 |
| eGFR | Diabetes duration, years | 530 | 12.09 ± 7.82 | 439 | 12.34 ± 8.15 | -0.032 | 0.459 |
| eGFR | Hypertension | 571 | 535 (93.7%) | 518 | 481 (92.9%) | 0.033 | 0.581 |
| eGFR | Coronary disease history | 567 | 189 (33.3%) | 501 | 163 (32.5%) | 0.017 | 0.782 |
| eGFR | Heart failure | 565 | 77 (13.6%) | 492 | 69 (14.0%) | -0.011 | 0.852 |
| eGFR | Baseline eGFR, mL/min/1.73 m² | 571 | 58.51 ± 22.91 | 476 | 58.55 ± 25.68 | -0.002 | 0.532 |
| eGFR | Baseline potassium, mEq/L | 567 | 4.49 ± 0.39 | 485 | 4.49 ± 0.42 | -0.008 | 0.915 |
| eGFR | Baseline log UACR | 482 | 6.50 ± 1.34 | 388 | 6.24 ± 1.59 | 0.180 | 0.021 |
| eGFR | HbA1c, % | 525 | 7.79 ± 1.79 | 428 | 7.76 ± 1.72 | 0.019 | 0.963 |
| eGFR | Systolic BP, mmHg | 513 | 133.98 ± 15.04 | 420 | 135.74 ± 17.60 | -0.107 | 0.383 |
| eGFR | Finerenone 20 mg | 559 | 82 (14.7%) | 499 | 77 (15.4%) | -0.021 | 0.729 |
| eGFR | SGLT2i use | 571 | 504 (88.3%) | 504 | 431 (85.5%) | 0.082 | 0.181 |
| eGFR | Maximal RAS blockade | 541 | 373 (68.9%) | 448 | 264 (58.9%) | 0.210 | 0.001 |
| eGFR | Thiazide use | 568 | 226 (39.8%) | 496 | 210 (42.3%) | -0.052 | 0.399 |
| eGFR | Loop diuretic use | 567 | 87 (15.3%) | 496 | 75 (15.1%) | 0.006 | 0.920 |
| eGFR | GLP-1 RA use | 570 | 38 (6.7%) | 503 | 10 (2.0%) | 0.231 | <0.001 |
| Potassium | Age, years | 647 | 60.53 ± 11.28 | 443 | 60.74 ± 11.79 | -0.018 | 0.474 |
| Potassium | Male sex | 647 | 368 (56.9%) | 444 | 232 (52.3%) | 0.093 | 0.131 |
| Potassium | BMI, kg/m² | 532 | 30.43 ± 5.96 | 324 | 30.39 ± 5.80 | 0.006 | 0.715 |
| Potassium | Diabetes duration, years | 595 | 12.36 ± 8.08 | 374 | 11.96 ± 7.78 | 0.050 | 0.812 |
| Potassium | Hypertension | 646 | 608 (94.1%) | 443 | 408 (92.1%) | 0.080 | 0.191 |
| Potassium | Coronary disease history | 644 | 210 (32.6%) | 424 | 142 (33.5%) | -0.019 | 0.764 |
| Potassium | Heart failure | 639 | 89 (13.9%) | 418 | 57 (13.6%) | 0.008 | 0.893 |
| Potassium | Baseline eGFR, mL/min/1.73 m² | 637 | 58.62 ± 23.14 | 410 | 58.39 ± 25.78 | 0.010 | 0.403 |
| Potassium | Baseline potassium, mEq/L | 647 | 4.48 ± 0.39 | 405 | 4.50 ± 0.43 | -0.062 | 0.220 |
| Potassium | Baseline log UACR | 536 | 6.48 ± 1.33 | 334 | 6.22 ± 1.63 | 0.174 | 0.059 |
| Potassium | HbA1c, % | 593 | 7.74 ± 1.75 | 360 | 7.84 ± 1.77 | -0.058 | 0.298 |
| Potassium | Systolic BP, mmHg | 581 | 134.34 ± 15.07 | 352 | 135.49 ± 18.04 | -0.070 | 0.858 |
| Potassium | Finerenone 20 mg | 635 | 96 (15.1%) | 423 | 63 (14.9%) | 0.006 | 0.920 |
| Potassium | SGLT2i use | 647 | 571 (88.3%) | 428 | 364 (85.0%) | 0.094 | 0.126 |
| Potassium | Maximal RAS blockade | 606 | 419 (69.1%) | 383 | 218 (56.9%) | 0.255 | <0.001 |
| Potassium | Thiazide use | 644 | 248 (38.5%) | 420 | 188 (44.8%) | -0.127 | 0.043 |
| Potassium | Loop diuretic use | 643 | 100 (15.6%) | 420 | 62 (14.8%) | 0.022 | 0.726 |
| Potassium | GLP-1 RA use | 646 | 42 (6.5%) | 427 | 6 (1.4%) | 0.264 | <0.001 |
| UACR | Age, years | 476 | 59.56 ± 11.42 | 614 | 61.43 ± 11.48 | -0.164 | 0.004 |

| Outcome | Variable | Complete n | Complete | Incomplete n | Incomplete | SMD | P |
|---|---|---|---|---|---|---|---|
| UACR | Male sex | 476 | 277 (58.2%) | 615 | 323 (52.5%) | 0.114 | 0.062 |
| UACR | BMI, kg/m² | 384 | 30.47 ± 5.85 | 472 | 30.37 ± 5.94 | 0.017 | 0.651 |
| UACR | Diabetes duration, years | 441 | 11.74 ± 7.95 | 528 | 12.59 ± 7.96 | -0.107 | 0.020 |
| UACR | Hypertension | 476 | 442 (92.9%) | 613 | 574 (93.6%) | -0.031 | 0.609 |
| UACR | Coronary disease history | 472 | 141 (29.9%) | 596 | 211 (35.4%) | -0.118 | 0.056 |
| UACR | Heart failure | 471 | 52 (11.0%) | 586 | 94 (16.0%) | -0.147 | 0.019 |
| UACR | Baseline eGFR, mL/min/1.73 m² | 467 | 59.64 ± 22.87 | 580 | 57.64 ± 25.20 | 0.083 | 0.045 |
| UACR | Baseline potassium, mEq/L | 471 | 4.49 ± 0.39 | 581 | 4.48 ± 0.41 | 0.028 | 0.716 |
| UACR | Baseline log UACR | 476 | 6.52 ± 1.30 | 394 | 6.22 ± 1.62 | 0.208 | 0.015 |
| UACR | HbA1c, % | 439 | 7.78 ± 1.79 | 514 | 7.78 ± 1.73 | -0.004 | 0.660 |
| UACR | Systolic BP, mmHg | 428 | 134.39 ± 14.84 | 505 | 135.10 ± 17.37 | -0.044 | 0.988 |
| UACR | Finerenone 20 mg | 464 | 71 (15.3%) | 594 | 88 (14.8%) | 0.014 | 0.826 |
| UACR | SGLT2i use | 476 | 425 (89.3%) | 599 | 510 (85.1%) | 0.124 | 0.045 |
| UACR | Maximal RAS blockade | 460 | 315 (68.5%) | 529 | 322 (60.9%) | 0.160 | 0.013 |
| UACR | Thiazide use | 474 | 186 (39.2%) | 590 | 250 (42.4%) | -0.064 | 0.302 |
| UACR | Loop diuretic use | 473 | 67 (14.2%) | 590 | 95 (16.1%) | -0.054 | 0.383 |
| UACR | GLP-1 RA use | 475 | 35 (7.4%) | 598 | 13 (2.2%) | 0.246 | <0.001 |

*SMD, standardized mean difference. Absolute SMDs of approximately 0.10 and 0.20 indicate small and potentially important observed imbalances, respectively. P values are descriptive.*

**Supplementary Figure S1. Standardized mean differences for paired UACR availability**



## Supplementary Table S2A. eGFR changes by exploratory subgroup

| Family | Subgroup | n | Mean change | 95% CI | P-heterogeneity |
|---|---|---|---|---|---|
| Starting dose | Starting dose: 10 mg | 477 | -2.500 | -3.318 to -1.682 | 0.989 |
| Starting dose | Starting dose: 20 mg | 82 | -3.945 | -6.011 to -1.879 | 0.989 |
| SGLT2 inhibitor | SGLT2i: No | 67 | -1.613 | -3.745 to 0.519 | 0.472 |
| SGLT2 inhibitor | SGLT2i: Yes | 504 | -2.800 | -3.596 to -2.004 | 0.472 |
| CKD category | CKD G1-G2 (≥60) | 228 | -4.037 | -5.522 to -2.552 | 0.241 |
| CKD category | CKD G3a (45-59) | 152 | -2.579 | -3.904 to -1.253 | 0.241 |
| CKD category | CKD G3b (30-44) | 160 | -0.971 | -1.874 to -0.068 | 0.241 |
| CKD category | CKD G4-G5 (<30) | 31 | -1.670 | -3.530 to 0.189 | 0.241 |

## Supplementary Table S2B. Potassium changes by exploratory subgroup

| Family | Subgroup | n | Mean change | 95% CI | P-heterogeneity |
|---|---|---|---|---|---|
| Starting dose | Starting dose: 10 mg | 539 | 0.289 | 0.250 to 0.327 | 0.514 |
| Starting dose | Starting dose: 20 mg | 96 | 0.382 | 0.277 to 0.488 | 0.514 |
| SGLT2 inhibitor | SGLT2i: No | 76 | 0.320 | 0.216 to 0.425 | 0.828 |
| SGLT2 inhibitor | SGLT2i: Yes | 571 | 0.303 | 0.265 to 0.341 | 0.828 |
| CKD category | CKD G1-G2 (≥60) | 254 | 0.279 | 0.226 to 0.333 | 0.025 |
| CKD category | CKD G3a (45-59) | 172 | 0.308 | 0.238 to 0.378 | 0.025 |
| CKD category | CKD G3b (30-44) | 174 | 0.345 | 0.273 to 0.418 | 0.025 |
| CKD category | CKD G4-G5 (<30) | 37 | 0.262 | 0.085 to 0.439 | 0.025 |

## Supplementary Table S2C. UACR geometric mean ratios by exploratory subgroup

| Family | Subgroup | n | Geometric mean ratio | 95% CI | P-heterogeneity |
|---|---|---|---|---|---|
| Starting dose | Starting dose: 10 mg | 392 | 0.539 | 0.498 to 0.583 | 0.921 |
| Starting dose | Starting dose: 20 mg | 71 | 0.536 | 0.455 to 0.632 | 0.921 |
| SGLT2 inhibitor | SGLT2i: No | 51 | 0.701 | 0.564 to 0.871 | 0.089 |
| SGLT2 inhibitor | SGLT2i: Yes | 424 | 0.529 | 0.491 to 0.569 | 0.089 |
| CKD category | CKD G1-G2 (≥60) | 195 | 0.578 | 0.522 to 0.641 | 0.088 |
| CKD category | CKD G3a (45-59) | 126 | 0.508 | 0.438 to 0.590 | 0.088 |
| CKD category | CKD G3b (30-44) | 125 | 0.532 | 0.462 to 0.612 | 0.088 |
| CKD category | CKD G4-G5 (<30) | 20 | 0.628 | 0.483 to 0.817 | 0.088 |

*All subgroup analyses are exploratory. Heterogeneity P values are baseline-adjusted interaction/omnibus tests; no multiplicity adjustment was applied.*

**Supplementary Figure S2A. eGFR mean changes and 95% CIs by subgroup.**



**Supplementary Figure S2B. Potassium mean changes and 95% CIs by subgroup.**



**Supplementary Figure S2C. UACR geometric mean ratios and 95% CIs by subgroup.**



## Supplementary Table S3. Albuminuria sensitivity analysis by urine collection method

| Analysis | n | Median reduction [IQR] | ≥30% response | ≥50% response | Geometric mean ratio |
|---|---|---|---|---|---|
| Spot urine only | 341 | 46.1% [16.4–66.3] | 213 (62.5%) | 153 (44.9%) | 0.516 |
| All supplied UACR/proteinuria records | 476 | 39.2% [16.9–62.1] | 297 (62.4%) | 184 (38.7%) | 0.545 |

*The spot-only analysis is a sensitivity analysis pending confirmation that values labeled as 24-hour collection are directly comparable and expressed in the same units as spot UACR.*